Processa Pharmaceuticals Inc.

02/07/2024 | Press release | Distributed by Public on 02/07/2024 17:02

Submission of Matters to a Vote of Security Holders Form 8 K

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 28, 2024, the Company held its 2024 Annual Meeting of Shareholders (the "Annual Meeting"). Present at the Annual Meeting in person or by proxy were holders of shares of common stock of the Company, representing at least a majority of the voting power of the common stock of the Company issued and outstanding and entitled to vote as of the close of business on April 29, 2024, the record date for the Meeting, and constituting a quorum for the transaction of business.

At the Annual Meeting, the shareholders of the Company voted on the following four proposals:

1. The election of all six directors to serve until the next Annual Meeting of Shareholders or until their successors have been duly elected and qualified based on the following votes:
Shares
Name For Against Abstain Broker Non-Votes
Justin Yorke 878,203 - 96,316 568,993
George Ng 882,583 - 91,936 568,993
Khoso Baluch 878,995 - 95,524 568,993
James Neal 879,256 - 95,263 568,993
Geraldine Pannu 878,944 - 95,575 568,993
Dr, David Young 896,694 - 77,825 568,993
2. The amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan to increase the number of shares available for issuance under the Plan by 500,000 shares was approved based on the following votes:
Shares
For Against Abstain Broker Non-Vote
779,164 176,802 18,553 568,993
3. The appointment of BD & Company, Inc. as the independent registered public accounting firm for 2024 was ratified based on the following votes:
Shares
For Against Abstain Broker Non-Vote
1,490,908 32,346 20,258 -
4. The advisory vote relating to compensation of our named executive officers was approved based on the following votes:
Shares
For Against Abstain Broker Non-Vote
804,087 164,034 6,398 568,993